Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Aurobindo Pharma Subsidiary Buys Khandelwal Non-Oncology Business for ₹325 Crore

Synopsis:


Auro Pharma, a wholly owned subsidiary of Aurobindo Pharma, has acquired Khandelwal Laboratories’ non-oncology prescription formulations business for ₹325 crore. The business comprises 23 brands, 67 SKUs and nine pipeline products with a turnover of ₹1,135.3 million in FY 2024-25.


Source: Aurobindo Pharma Press Release (NSE Exchange Fillings) | Published on Jan 01, 2025

Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

As quoted in the press release of Aurobindo Pharma (NSE Exchange Filings), the branded non-oncology prescription formulations business of Khandelwal Laboratories Private Limited has been purchased by Auro Pharma Limited, which is 100% owned by Aurobindo Pharma. The total purchase price is ₹325 crore and was done on a "going concern" basis. The Business Transfer Agreement was finalized on 1 January 2026.

Also Read: RailTel Secures ₹56.71 Crore HMIS Order from Assam Body

Aurobindo Pharma Ltd

Trade

1204.111.09 (0.92 %)

Updated - 02 January 2026
1206.70day high
DAY HIGH
1192.00day low
DAY LOW
412064
VOLUME (BSE)

Key Takeaways

  • Auro Pharma acquired the non-oncology prescription formulations business of Khandelwal Laboratories on a slump sale and going concern basis.

  • The acquired portfolio includes 23 marketed brands, 67 SKUs and nine pipeline products.

  • Anti-infective and pain management products are significant parts of the acquired business.

  • In FY 2024-25, the business recorded a turnover of ₹1,135.3 million with EBITDA of ₹289.9 million.

  • The business operates with about 470 field staff and more than 1,600 stockists and distribution points.

Also read: Vodafone Idea Receives ₹637.9 Crore GST Penalty Order

Details Of The Acquired Business

The acquisition target is the branded prescription formulations, other than the oncology business segment of Khandelwal Laboratories. The acquisition transaction includes not only the product inventory and associated intellectual property, but also the workforce and contracts related to this business. A primary goal of this acquisition structure is the continued protection of this business as a going concern. The business has a product portfolio of anti-infectives and pain management products available for purchase in the Indian market through a strong distribution network developed over many years.

In the last three years of financial records, the business has been able to achieve total revenues of ₹1,049.8 million for FY 2022-23, ₹1,146.9 million for FY 2023-24 and ₹1,135.3 million for FY 2024-25. This has allowed for a relatively stable level of turnover. The business employs approximately 470 field force personnel who distribute through a national network of more than 1,600 stockists.

Strategic Fit and Operational Notes

Auro Pharma will expand its existing product lines by acquiring additional branded products for sale in the domestic formulations market. The company expects new pain management and anti-infective products to augment the other pain management and anti-infective medications it currently sells to consumers. No governmental or regulatory approvals were required to complete the transaction; it was completed on a cash basis.

The transaction does not include either the issuance of shares to the buyer or a share swap with the seller, nor does it transfer control of Khandelwal Laboratories. The only thing being transferred is the business segment itself, with all present and future obligations remaining with Khandelwal Labs. Any adjustments made in connection with the working capital true-up will apply as provided in the definitive agreements executed in connection with this transaction.

Share Price Update

Aurobindo Pharma share price stands at ₹1,193 per share on the BSE as of 1 Jan 2026 at 15:30 PM IST, up 0.85% compared with the previous session.

Published Date : 02 Jan 2026

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.8 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,900+ Cr MTF Book

icon-with-text